SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma India informs about press release

11 Mar 2024 Evaluate
Astrazeneca Pharma India has enclosed copy of press release in connection with a Distribution and Promotion Agreement entered into by the Company with Mankind Pharma for the distribution of budesonide and formoterol fumarate dihydrate (brand name Symbicort) in India. Further, details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached as Annexure - A, in this regard.

The above information is a part of company’s filings submitted to BSE. 

Astrazeneca Pharma I Share Price

8425.15 181.25 (2.20%)
15-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1806.45
Dr. Reddys Lab 1279.25
Cipla 1381.50
Zydus Lifesciences 1087.75
Lupin 2273.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: